Skip to main content

Table 36 Mirtazapine for children and adolescents with Anorexia Nervosa

From: Canadian practice guidelines for the treatment of children and adolescents with eating disorders

Certainty assessment

Impact

Certainty

Importance

№ of studies

Study design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

Weight (assessed with: kg)

 1

Case Control

serious a

not serious

not serious

not serious

none

9 females with AN treated with mirtazapine (mean dose 21.7 mg/day) matched with 9 controls. No significant differences in weight or BMI at the end of 4 weeks of treatment.

VERY LOW

CRITICAL

Weight (assessed with: kg) Depression (assessed with: clinical impression)

 2

Case Reports

very serious a,b

not serious

not serious

not serious

none

Two case reports (one male, one female) with AN and depression. Both improved in weight.

VERY LOW

CRITICAL

very serious a,b

not serious

not serious

not serious

none

One of these case reports mentioned remission of depression in the context of AN with treatment with mirtazapine (30 mg).

VERY LOW

CRITICAL

  1. Explanations
  2. asubjects were not randomized
  3. bno control condition
  4. Bibliography:
  5. Case Control - Hrdlicka 2008 [179]
  6. Case Report - Jaafar 2007 [180], Naguy 2018 [181]